title: Is there a best transplant conditioning regimen for acute myeloid leukemia?
abstract: The outcome of marrow transplantation is largely determined by the effectiveness of the transplant preparative regimen. Nonetheless, there have been startlingly few randomized trials attempting to identify optimal regimens for specific conditions and, at present, no single approach has emerged as superior for the treatment of acute myeloid leukemia (AML) in the few trials that have been performed. Newer approaches that appear encouraging in phase II studies include substituting etoposide for cyclophosphamide, adding thiotepa to the traditional cyclophosphamide plus total body irradiation combination in the setting of T cell depletion, and using antibody-based targeted radiotherapy as part of the transplant regimen. The ability to obtain allogeneic engraftment with nonablative regimens may open the door to additional innovative approaches, combining very specific antileukemia therapy with relatively nontoxic measures to ensure engraftment.
authors.affiliation: Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle 98109-1024, USA.
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
mesh_terms: D000208:Acute Disease; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007951:Leukemia, Myeloid / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods*; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa